Stock News

278.79% to Target, H.C. Wainwright Reconfirms “Buy” Rating for Veru (VERU) Stock; SolarEdge Technologies, Inc. (SEDG) Had 13 Analysts Last Week

Among 18 analysts covering SolarEdge Technologies (NASDAQ:SEDG), 13 have Buy rating, 4 Sell and 1 Hold. Therefore 72% are positive. SolarEdge Technologies had 60 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of SolarEdge Technologies, Inc. (NASDAQ:SEDG) has “Buy” rating given on Thursday, August 13 by TH Capital. The firm has “Hold” rating given on Monday, November 27 by Deutsche Bank. Needham maintained SolarEdge Technologies, Inc. (NASDAQ:SEDG) rating on Thursday, November 5. Needham has “Buy” rating and $34 target. On Wednesday, July 12 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm has “Buy” rating by Needham given on Tuesday, May 10. The firm earned “Buy” rating on Friday, October 13 by Roth Capital. Needham maintained the stock with “Buy” rating in Tuesday, September 12 report. On Friday, November 3 the stock rating was maintained by Roth Capital with “Buy”. The stock of SolarEdge Technologies, Inc. (NASDAQ:SEDG) has “Mkt Perform” rating given on Thursday, November 10 by FBR Capital. The firm has “Overweight” rating given on Wednesday, August 10 by Barclays Capital. See SolarEdge Technologies, Inc. (NASDAQ:SEDG) latest ratings:

11/01/2018 Broker: Vertical Group Rating: Sell Initiates Coverage On
27/11/2017 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $30 Downgrade
09/11/2017 Broker: Cowen & Co Rating: Buy New Target: $41.0 Maintain
09/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $43.0
09/11/2017 Broker: Needham Rating: Buy New Target: $42.0 Maintain
09/11/2017 Broker: Roth Capital Rating: Buy New Target: $42.0 Maintain
09/11/2017 Broker: B. Riley & Co Old Rating: Neutral New Rating: Buy Upgrade
09/11/2017 Broker: FBR Capital Rating: Buy New Target: $45.0 Upgrade
06/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $30 New Target: $36 Maintain
03/11/2017 Broker: Roth Capital Rating: Buy New Target: $36.0 Maintain

The stock increased 0.76% or $0.01 during the last trading session, reaching $1.32. About 70,479 shares traded. Veru Inc. (VERU) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

SolarEdge Technologies, Inc., together with its subsidiaries, designs, develops, and sells direct current optimized inverter systems for solar photovoltaic (PV) installations in Israel, Europe, the United States, and internationally. The company has market cap of $1.59 billion. The companyÂ’s DC optimized inverter systems include power optimizers, inverters, and cloud monitoring software. It has a 26.39 P/E ratio. The Company’s products are used in a range of solar market divisions, including residential, commercial, and small utility-scale solar installations.

The stock increased 2.50% or $0.9 during the last trading session, reaching $36.9. About 1.10M shares traded or 56.87% up from the average. SolarEdge Technologies, Inc. (NASDAQ:SEDG) has declined 7.10% since February 15, 2017 and is downtrending. It has underperformed by 23.80% the S&P500.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products. The company has market cap of $70.64 million. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It currently has negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

Leave a Reply

Your email address will not be published. Required fields are marked *